Humana launches oncology model to ease prior authorization for cancer drugs

Humana has launched a cancer care model aimed at easing the prior authorization process for oncology providers, according to a Nov. 10 Humana news release reported by Becker's Hospital Review. The model was developed with the American Oncology Network, which spans more than 350 providers across 21 states, and specialty care management company Evolent. The network has rolled out the model at its clinics in eight states, per Becker's Payer Issues.

The mechanics matter more than the announcement. Under the model, practices that meet quality and evidence-based treatment standards can bypass the traditional prior authorization process for most anticancer drugs. In effect, the payer is trading case-by-case review for an upfront qualification standard. Participating practices also get access to an analytics platform that draws on real-time EHR data to inform individualized treatment plans, the release said.

For finance and revenue cycle leaders, this is a shift in where the administrative work lives. Instead of staff assembling and chasing individual requests, the effort moves to demonstrating and maintaining adherence to quality and evidence-based standards. That can mean fewer touches per claim, but it also means a practice's documentation and data quality become the gate to the benefit. For chief medical officers and physicians, the appeal is fewer delays between a treatment decision and the start of therapy, and less time spent on payer paperwork. For the Chief AI Officer, the analytics layer running on real-time EHR data raises the usual questions about data flows, integration effort and who governs the recommendations it produces.

What the evidence does not yet show is equally important. Humana says the model is aimed at easing prior authorization, but no published results on approval times, denial rates or administrative workload exist yet. The sources do not specify which drugs fall outside the "most anticancer drugs" covered, what the quality thresholds are, or whether participation extends beyond the American Oncology Network.

The move: have revenue cycle and oncology leaders pull current Humana prior authorization volume, turnaround times and staff hours for anticancer drugs, then compare that baseline against the model's terms. Ask Humana directly whether participation is open to your group, what the qualifying standards are, and how performance is measured over time. A documented baseline now is what will let you judge whether the model returns real time to clinicians and faster treatment starts for patients.

You are a revenue cycle advisor to the CFO and executive team of [your organization], an oncology practice or health system that bills Humana.

According to a Nov. 10 Humana news release reported by Becker's Hospital Review and Becker's Payer Issues, Humana has launched a cancer care model aimed at easing prior authorization for oncology providers. It was developed with the American Oncology Network, which spans more than 350 providers across 21 states, and with the specialty care management company Evolent. The network has rolled the model out at its clinics in eight states. Practices that meet quality and evidence-based treatment standards can bypass the traditional prior authorization process for most anticancer drugs. Participating practices also get an analytics platform that draws on real-time EHR data. No published results on approval times, denial rates or administrative workload exist yet. The sources do not say which drugs are excluded, what the quality thresholds are, or whether participation extends beyond the American Oncology Network.

Your task is to compare our current Humana prior authorization baseline for anticancer drugs against these terms and to prepare the questions we will put to Humana about whether participation is open to our group.

Produce a one-page memo for the executive team with these sections: Current baseline; What the model would change; Gaps and unknowns; Questions for Humana, covering eligibility, qualifying standards, how performance is measured over time, excluded drugs, and EHR integration and governance of the analytics platform; Recommended next step with an owner.

Use these inputs: [your monthly Humana prior authorization volume for anticancer drugs], [your average turnaround time in days], [staff hours per month spent on these requests], [your EHR], [the names of your revenue cycle and oncology leads].

Use only the facts given here and the slots I have filled. Cite Becker's Hospital Review and Becker's Payer Issues by name. Flag anything uncertain or that must be verified with Humana. Do not request or include patient data. Nothing here is medical advice. Label the memo as a draft for the team to check.